SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Supernus Pharmaceuticals, Inc.

Levi & Korsinsky announces it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") SUPN concerning possible violations of federal securities laws.

On September 18, 2017, Supernus issued a press release announcing interim results for its first Phase 3 clinical trial for SPN-810. In the same release, Supernus announced it would eliminate the 18mg dose arm. To obtain additional information, go to:

http://www.zlkdocs.com/SUPN-Info-Request-Form-6163

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171020005767/en/